Home/Celcuity/Lance Laing, PhD
LL

Lance Laing, PhD

Chief Science Officer and Co-founder

Celcuity

Celcuity Pipeline

DrugIndicationPhase
Gedatolisib + Palbociclib + FulvestrantHR+/HER2- Advanced Breast Cancer (PIK3CA Wild-Type)Phase 3
Gedatolisib + Palbociclib + Letrozole/FulvestrantHR+/HER2- Advanced Breast Cancer (PIK3CA Mutant)Phase 3
Gedatolisib + DarolutamideMetastatic Castration-Resistant Prostate Cancer (mCRPC)Phase 1b/3